More Investment In China’s Health Care System Unveiled During NPC; Is It Time To Ask Who Will Benefit First And Most?
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - With the world economy in a downturn, the annual session of China's National People's Congress, one of the most important meetings in the country, is being held in Beijing
You may also be interested in...
Novartis To Pay $125 Million To Acquire Chinese Vaccine Maker
SHANGHAI - After disclosing this week that the company intends to channel a remarkable $1 billion into expanding an R&D center in Shanghai, Novartis revealed that it will pay $125 million to acquire an 85 percent stake in Zhejiang Tianyuan, the second-largest H1N1 vaccine provider in China
Novartis To Pay $125 Million To Acquire Chinese Vaccine Maker
SHANGHAI - After disclosing this week that the company intends to channel a remarkable $1 billion into expanding an R&D center in Shanghai, Novartis revealed that it will pay $125 million to acquire an 85 percent stake in Zhejiang Tianyuan, the second-largest H1N1 vaccine provider in China
Western Firms Prepare To Capitalize On Chinese Reimbursement Reform
Western drug-makers are positioning themselves to capitalize on a multi-billion dollar health care reform program outlined by the Chinese government earlier this year